{'fraction_non_alphanumeric': 0.043164994242474095, 'fraction_numerical': 0.031255140648132916, 'mean_word_length': 4.954162585700294, 'pattern_counts': {'":': 0, '<': 20, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Polydatin prevents fructose-induced liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway

Oxidative stress is a critical factor in nonalcoholic fatty liver disease pathogenesis. MicroRNA-200a (miR-200a) is reported to target Kelch-like ECH-associated protein 1 (Keap1), which regulates nuclear factor erythroid 2-related factor 2 (Nrf2) anti-oxidant pathway. Polydatin (3,4′,5-trihydroxy-stilbene-3-β-D-glucoside), a polyphenol found in the rhizome of Polygonum cuspidatum, have anti-oxidative, anti-inflammatory and anti-hyperlipidemic effects. However, whether miR-200a controls Keap1/Nrf2 pathway in fructose-induced liver inflammation and lipid deposition and the blockade of polydatin are still not clear. Here, we detected miR-200a down-regulation, Keap1 up-regulation, Nrf2 antioxidant pathway inactivation, ROS-driven thioredoxin-interacting protein (TXNIP) over-expression, NOD-like receptor (NLR) family, pyrin domain containing 3 (NLRP3) inflammasome activation and dysregulation of peroxisome proliferator activated receptor-α (PPAR-α), carnitine palmitoyl transferase-1 (CPT-1), sterol regulatory element binging protein 1 (SREBP-1) and stearoyl-CoA desaturase-1 (SCD-1) in rat livers, BRL-3A and HepG2 cells under high fructose induction. Furthermore, the data from the treatment or transfection of miR-200a minic, Keap1 and TXNIP siRNA, Nrf2 activator and ROS inhibitor demonstrated that fructose-induced miR-200a low-expression increased Keap1 to block Nrf2 antioxidant pathway, and then enhanced ROS-driven TXNIP to activate NLRP3 inflammasome and disturb lipid metabolism-related proteins, causing inflammation and lipid deposition in BRL-3A cells. We also found that polydatin up-regulated miR-200a to inhibit Keap1 and activate Nrf2 antioxidant pathway, resulting in attenuation of these disturbances in these animal and cell models. These findings provide a novel pathological mechanism of fructose-induced redox status imbalance and suggest that the enhancement of miR-200a to control Keap1/Nrf2 pathway by polydatin is a therapeutic strategy for fructose-associated liver inflammation and lipid deposition.

There is crosstalk between oxidative stress and microRNA-200a (miR-200a). MiR-200a high-expression by targeting Keap1 inhibition up-regulates Nrf2 nuclear translocation as well as glutathione S-transferase (GST), hemeoxygenase-1 (HO-1) and NQO1 protein levels, and then decreases ROS production in human adult cardiomyocyte line exposed to hypoxia [12], and increases tumor necrosis factor-α (TNF-α) and IL-6 at mRNA levels, as well as down-regulates peroxisome proliferator activated receptor-α (PPAR-α), and up-regulates SCD1 and SREBP-1c at protein levels in fructose-exposed HepG2 cells [13]. It is attractive therefore to hypothesize that aberrant miR-200a expression may target to Keap1 and then inhibit Nrf2 antioxidant pathway, participating in fructose-induced liver inflammation and lipid deposition.
Anti-oxidant agent polydatin (3,4′,5-trihydroxy-stilbene-3-β-D-glucoside), a natural precursor of resveratrol, is isolated from Polygonum cuspidatum Siebold & Zucc, which has been used in traditional Chinese medicine to treat liver disorders associated with oxidative stress, inflammation and lipid deposition for centuries in patients [14] and in experimental animals [15,16]. Polydatin decreases malondialdehyde (MDA) levels and increases GST activity in the liver of carbon tetrachloride-or D-galactose-stimulated mice, with the reduction of TNF-α and IL-1β gene expression [17,18]. It inhibits Keap1, promotes Nrf2 transcriptional activity, increases HO-1 protein levels, and quenches ROS generation in advanced glycation-end products-simulated rat glomerular mesangial cells [19]. Additionally, polydatin suppresses kidney NLRP3 inflammasome activation in potassium oxonate-treated rats [20], increases liver PPAR-α protein levels in streptozocin-induced diabetic mice fed with high-fat and sugar diet [21], and decreases liver SCD-1 protein levels in high-fat diet-fed rats [22]. Thus, it is important to understand the molecular mechanism underlying its attenuation of fructose-induced redox status imbalance in liver inflammation and lipid deposition.
In this study, we showed that high fructose decreased miR-200a to target Keap1 and inhibit Nrf2 antioxidant pathway, and then triggered TXNIP-activated NLRP3 inflammasome, causing liver inflammation and lipid deposition. Furthermore, polydatin reduced oxidative stress by increasing miR-200a to regulate Keap1/Nrf2 pathway, resulting in the protection against fructose-induced liver inflammation and lipid deposition. Therefore, the ability of high miR-200a expression to control Keap1/Nrf2 pathway by polydatin may be a new therapeutic strategy.

Animals and treatment
Male Sprague-Dawley rats aged from 6 to 7 weeks (180-220 g) were purchased from Experimental Animal Center of Zhejiang province (Hangzhou, China) (Production license: SCXK 2014-0001). They were housed in Laboratory Animal Care of Life Science College under controlled temperature (22 ± 2°C) and relative humidity (55 ± 5%) with a normal 12-h light/dark cycle. Animal welfare and experimental procedures were carried out in accordance with the criteria outlined in the 'Guide for the Care and Use of Laboratory Animals' enacted by National Academy of Sciences and published by the National Institutes of Health (NIH publication 86-23 revised 1985) and the related ethnical regulations of Nanjing University [SYXK (SU) 2009-0017]. All animal experimental protocols were approved by the Institutional Animal Care and Use Committee of Nanjing University. All efforts were made to minimize animal suffering and to reduce the number of animals used.
Rats ad libitum accessed a standard chow and water for one week acclimatization before the experiment. To evaluate the protection of polydatin and pioglitazone in fructose-induced liver oxidative stress, inflammation and lipid deposition, rats were randomized into the following six groups (n = 8): control vehicle, fructose vehicle, fructose with polydatin (7.5, 15, 30 mg/kg) as well as fructose with pioglitazone (positive drug, 4 mg/kg). Each rat was given drinking water or 100 mL drinking water containing 10% fructose (wt/vol) for 6 weeks, and followed by the treatment of saline injection, polydatin, or pioglitazone table by intragastric administration for next 7 weeks. All drugs were administered once daily between 2:30 p.m. and 3:30 p.m.. Animal body weight was detected weekly. Doses of polydatin and pioglitazone were selected based on our preliminary studies and other reports [22][23][24][25][26][27].

Histological study
Light microscopy and histological examination of tissue sections stained with H&E reagent and oil-red O solution were carried out to evaluate whether high fructose intake induced liver inflammation and lipid deposition, and the effects of polydatin and pioglitazone on these pathological changes in rats.

Cell culture and treatment
Cell lines of Buffalo rat liver cells (BRL-3A) and HepG2 were supported by Shanghai Institutes for Biological Sciences (Shanghai, China). These cells were grown in DMEM (4.5 mg/mL glucose), supplemented with 10% fetal bovine serum in a humidified 5% CO 2 atmosphere at 37°C, respectively.
MiR-200a mimic, Keap1 siRNA, TXNIP siRNA as well as these respective negative controls were synthesized by GenePharma Co., Ltd (Shanghai, China), respectively. The sequences of these oligonucleotide fragments were listed in Supplementary Table 2. Transient transfection of 50 nM miR-200a mimic, 50 nM Keap1 siRNA, 50 nM TXNIP siRNA, or respective negative controls was performed using Lipofectamine 2000 following the manufacturer's protocols in BRL-3A cells for 6 h, respectively. These cells were then incubated in opti-MEM for other 18 h. qRT-PCR analysis of miR-200a, Keap1 and TXNIP expression levels and Western blot analysis of Keap1 and TXNIP protein levels were used to confirm the successful transfection, respectively. Then, miR-200a mimic or Keap1 siRNA-transfected BRL-3A cells were incubated with 5 mM fructose in the presence or absence of 40 μM polydatin or 10 μM pioglitazone in 6-well plates for 24 h to analyze Keap1, nuclear Nrf2, GST, HO-1 and NQO1 protein levels, for 48 h to detect TXNIP, NLRP3, ASC, Caspase-1, IL-1β, PPAR-α, CPT-1, SREBP-1 and SCD-1 protein levels by Western blot analysis; in 96-well plates for 24 h to detect ROS levels by labeling DCFH 2 -DA; for 48 h to assay TG and TC levels with standard diagnostic kits. BRL-3A cells were pretreated with 10 μM tBHQ (an activator of Nrf2) for 8 h, then incubated with 5 mM fructose in the presence or absence of 40 μM polydatin or 10 μM pioglitazone in 6-well plates for 24 h to analyze Keap1, nuclear Nrf2, GST, HO-1 and NQO1 protein levels, for 48 h to detect TXNIP, NLRP3, ASC, Caspase-1, IL-1β, PPAR-α, CPT-1, SREBP-1 and SCD-1 protein levels by Western blot analysis; in 96-well plates for 24 h to detect ROS levels by labeling DCFH 2 -DA; for 48 h to assay TG and TC levels with standard diagnostic kits. BRL-3A cells were co-cultured with 5 mM fructose and 5 mM NAC (ROS inhibitor) in the presence or absence of 40 μM polydatin or 10 μM pioglitazone in 6-well plates for 48 h to detect TXNIP protein levels by Western blot analysis. TXNIP siRNA-transfected BRL-3A cells were incubated with 5 mM fructose in the presence or absence of 40 μM polydatin or 10 μM pioglitazone in 6-well plates for 24 h to analyze nuclear Nrf2 protein levels, for 48 h to detect TXNIP, NLRP3, ASC, Caspase-1, IL-1β, PPAR-α, CPT-1, SREBP-1 and SCD-1 protein levels by Western blot analysis; in 96-well plates for 24 h to detect ROS levels by labeling DCFH 2 -DA; for 48 h to assay TG and TC levels with standard diagnostic kits, respectively.
Total cellular proteins, cytoplasm proteins, nuclear proteins and total RNAs were extracted, respectively. Experiments were repeated at least three times. These samples were stored at − 80°C before biochemical, qTR-PCR and Western blot analysis, respectively.

Determination of biochemical parameters
For IL-1β, TNF-α, MDA and H 2 O 2 assay, rat liver tissue samples were homogenized on ice in saline solution and then centrifuged at 2500 × g for 10 min at 4°C to get the supernatants. IL-1β and TNF-α levels in liver tissue supernatant or BRL-3A and HepG2 cells cultural supernatant were quantitated by ELISA kits, according to the instructions, respectively. MDA and H 2 O 2 levels in liver tissue supernatant were measured with commercial kits, respectively. For TG and TC assay, rat liver tissue samples were homogenized on ice in chloroform/ methanol (2:1) and then centrifuged at 2500 × g for 10 min at 4°C to get the supernatants. BRL-3A and HepG2 cells were lysed on ice in 2% Triton X-100 solution for 40 min followed by centrifugalization at 2500 × g for 10 min at 4°C to get the supernatants. TG and TC levels in liver tissue supernatant or cell lysate were determined with standard diagnostic kits, respectively. The protein contents of these samples were detected with BCA kit and normalized to the data of biochemical parameters.

ROS assay
ROS levels in liver tissue were detected with the fluorescence probe 2′ 7′-dichlorodihydrofluorescein diacetate (DCFH 2 -DA). For ROS assay, liver tissue was homogenized in saline solution and centrifuged 10,000 × g for 15 min at 4°C to get the supernatants. Five micromole probe DCFH2-DA (dissolved in PBS) was added into the supernatants at 37°C for 20 min. Fluorescence was measured at λ ex = 488 nM and λ em = 525 nm with a microplate reader (Thermo Scientific, Schwerte, Germany). The protein contents of liver samples were detected with BCA protein assay kit and normalized to the data of ROS levels.
Intracellular ROS levels in BRL-3A and HepG2 cells were quantified with the fluorescence probe DCFH 2 -DA. These cell samples were cocultured in DMEM without fetal bovine serum containing 5 μM DCFH 2 -DA at 37°C for 20 min. After washing with 0.01 M phosphate-buffered saline, fluorescence was detected at λ ex = 488 nM and λ em = 525 nm with a microplate reader. Then, these cell samples were exposed to 5 mg/mL 3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2-H-tetrazolium bromide (MTT) solution at 37°C for another 4 h. After centrifugalization at 2500 × g for 5 min at 4°C to remove supernatant, dimethyl sulphoxide was added to dissolve the precipitation. Absorbance at 570 nm was read on a plate reader. Cell activity was calculated and normalized to the data of ROS levels in BRL-3A and HepG2 cells.

Dual luciferase reporter assay
Wild-type or mutant of 3′UTR sequences of human Keap1 domain was cloned into the GP-miRGL0 control vector, with the primers listed in Supplementary Table 2. For the luciferase reporter assay, BRL-3A and HepG2 cells were co-transfected with 50 nM negative control or 50 nM of miR-200a mimic and 350 ng of wild-type of GP-miRGL0-Keap1-3′UTR vector. Simultaneously, BRL-3A and HepG2 cells were cotransfected with 50 nM negative control or 50 nM of miR-200a mimic and 350 ng of mutant-type of GP-miRGL0-Keap1-3′UTR vector. After 24 h transfection, cells were harvested. Firefly and Renilla luciferase activity was detected using Dual-luciferase Reporter Assay System kit according to the manufacturer's protocol.

qRT-PCR
Total RNA, from either frozen liver tissue or cultured cells, was extracted using Trizol reagent according to the instruction of the manufacture. First-strand complementary DNA synthesis for Keap1 and TXNIP were synthesized using the Reverse Transcription System Kit according to the manufacturer's instructions. Gene expression was quantified using iTaqTM Universal SYBR ® Green Supermix and genespecific primers listed in Supplementary Table 2. Expression of Keap1 and TXNIP were normalized to that of the housekeeping genes β-actin. The reverse transcription reactions of miR-200a was performed using 200 ng of purified total RNA, 0.75 μL of stem-loop RT primers listed in Supplementary Table 2 Table 2. Expression of miR-200a was normalized to the levels of U6. The ratio of the relative expression of target genes to the housekeeping genes was calculated by the 2 -ΔΔT method. All reactions were performed in triplicates for each sample.

Statistical analysis
Data are expressed as mean ± S.E.M.. One-way analysis of variance was used for comparison among the different groups, further analyzed by post hoc Dannelt testing. P < 0.05 was considered significant. Figures were obtained by the Statistical Analysis System (GraphPad Prism 5, GraphPad Software, Inc., San Diego, CA).

Polydatin alleviates hepatic oxidative stress, inflammation and lipid deposition in vivo and in vitro
In this study, polydatin reduced ROS (Table 1), MDA and H 2 O 2 levels (Supplementary Table 1), and down-regulated TXNIP mRNA and protein levels ( Fig. 1A and B) in the liver of fructose-fed rats. It also restored fructose feeding-induced inflammatory cells infiltrated in portal area of livers (Fig. 1C), high levels of IL-1β and TNF-α (Table 1) in rats. Consistently, polydatin down-regulated NLRP3, ASC and Caspase-1 protein levels as well as reduced IL-1β production in the liver of fructose-fed rats (Fig. 1D). Additionally, polydatin abrogated liver slight steatosis (Fig. 1C), increased PPAR-α and CPT-1 protein levels, decreased SREBP-1 and SCD-1 protein levels (Fig. 1D), and reduced TG and TC levels (Table 1) in the liver of fructose-fed rats. Pioglitazone exerted the similar effects in this animal model ( Fig. 1 and Table 1), except SREBP1 and ASC protein levels.

3.2.
Polydatin inhibits ROS/TXNIP to reduce inflammation and lipid deposition in fructose-exposed BRL-3A and HepG2 cells In earlier study using HepG2 cells, we found that ROS-induced TXNIP drove fructose-mediated hepatic inflammation and lipid deposition through NLRP3 inflammasome activation [2]. In the present study, to address blockade of ROS-driven TXNIP to reduce inflammation and lipid deposition, first, we treated fructose-exposed BRL-3A cells with NAC in the presence of polydatin or pioglitazone for 48 h, and found that polydtain and pioglitazone significantly down-regulated TXNIP protein levels (Fig. 3A).
production, restored deregulation of PPAR-α, CPT-1, SREBP-1 and SCD-1 (Fig. 3C) with high TG and TC levels ( Fig. 3D and E) in TXNIP siRNAtransfected BRL-3A cells with presence of fructose (48 h). These results suggest that blockade of fructose-induced oxidative stress by polydatin may be responsible for its attenuation of hepatic inflammation and lipid deposition.

Polydatin enhances miR-200a expression targeting Keap1 to activate Nrf2 antioxidant pathway in fructose-exposed BRL-3A and HepG2 cells with inflammation and lipid deposition
To further elucidate the mechanisms controlling Keap1/Nrf2 pathway in fructose-induced hepatic inflammation and lipid deposition, we detected miR-200a expression in response to fructose in cell cultures. Here, we noted that miR-200a expression profiling was significantly decreased in fructose-exposed BRL-3A (4 h) and HepG2 cells (12 h) (Fig. 6A), which were consistent with fructose-induced increase in Keap1 (Fig. 5A, B). Interestingly, TargetScan 5.2. predicted that Keap1 was as one of miR-200a target genes. To examine this prediction, the wild type 3′-UTR or the mutant 3′-UTR target sequence (Fig. 6B) were cloned into the luciferase reporter vector. These vectors were transfected into BRL-3A and HepG2 cells with miR-200a mimic, and found that miR-200a mimic significantly decreased wild type Keap1 3′-UTR reporter activity, but failed to alter mutant Keap1 3′-UTR reporter activity (Fig. 6B), the negative control affected neither wild type nor mutant Keap1 3′-UTR reporter activity (Fig. 6B). Additionally, Keap1 siRNA transfection was unable to alter miR-200a expression (4 h) (Fig. 6C) in BRL-3A co-cultured with fructose. These results provide the evidence that miR-200a may target the predicted site within the 3′-UTR of Keap1 mRNA.

Polydatin attenuates fructose feeding-induced miR-200a lowexpression, Keap1 up-regulation and Nrf2 antioxidant pathway inactivation in rats
To get an estimate of the potential relevance of these findings, we detected miR-200a expression and Keap1/Nrf2 pathway in the liver of fructose-fed rats with oxidative stress, inflammation and lipid disposition. Interestingly, we noticed a low-expression of liver miR-200a (Fig. 7A) in fructose-fed rats. We also observed fructose feeding upregulated Keap1 mRNA and protein levels (Fig. 7B), as well as downregulated nuclear Nrf2 (Fig. 7C), GST, HO-1 and NQO1 protein levels (Fig. 7D) in the liver of rats. Subsequently, we found that polydatin and pioglitazone increased miR-200a expression, down-regulated Keap1 and activated Nrf2 antioxidant pathway in this animal model (Fig. 7). A schematic model summarizing the mechanisms elucidated by our study was provided in Fig. 8.

Discussion
Non-alcoholic fatty liver disease is a common pathological manifestation of liver diseases and is known to aggravate the development of cirrhosis and hepatocellular carcinoma [1,29]. Fructose is present in industrialized foods and beverages in large amounts throughout the world. Clinical and experimental evidences demonstrate that excessive fructose consumption causes nonalcoholic fatty liver disease pathogenesis [1,2]. The enhanced oxidative stress signaling may underlie these events. Although clinical treatment with P. cuspidatum is available for the therapy of patients with many progressive liver diseases in Chinese medicine, the knowledge about the action of its main constituent polydatin is still fragmentary. Using an in vivo model induced by high fructose feeding, we provided evidence here that polydatin prevented miR-200a low-expression, Keap1 up-regulation and Nrf2 antioxidant pathway inactivation, being consistent with its reduction of liver inflammation and lipid deposition. Similar findings were obtained from in vitro studies using BRL-3A and HepG2 cells. These results provide new insight into the molecular factors that mediate the action of polydatin on fructose-induced oxidative stress, inflammation and lipid deposition and suggest new strategy for therapy.
Our previous study showed that ROS-driven TXNIP in fructose-induced liver inflammation and lipid deposition [2]. TXNIP binds to NLRP3 in response to ROS, causing NLRP3 inflammasome activation [8]. In this study, we also showed that TXNIP over-expression was a downstream event in ROS production in BRL-3A cells under high fructose stimulation. Of note, TXNIP siRNA only decreased one-third of TXNIP protein levels in fructose-exposed BRL-3A cells, possibly indicating that ROS-driven TXNIP and NLRP3 inflammasome activation was not completely interrupted. Thus, knockdown of TXNIP inhibited NLRP3 inflammasome activation and partly restored lipid metabolismrelated protein abnormal expression, resulting in reduction of TG and Relative protein levels of nuclear Nrf2 were normalized to LaminA, of Keap1, total Nrf2, GST, HO-1 and NQO1 were normalized to GAPDH or β-actin, respectively. All data are expressed as mean ± S.E.M.. P value was calculated by one-way ANOVA and further post hoc Dannelt testing. # P < 0.05, ## P < 0.01, ### P < 0.001 compared with control-vehicle; * P < 0.05, ** P < 0.01, *** P < 0.001 compared with fructose-vehicle. Keap1, Kelch-like ECH-associated protein 1.
Interestingly, Nrf2 antioxidant pathway is an essential cellular system to protect tissues from oxidative stress [30]. Specific Keap1 knockout prevents ethanol-induced ROS production, but Nrf2 deficiency aggravates ROS accumulation in mouse primary hepatocytes [11]. Nrf2 knockout induces heart TXNIP over-expression in diabetic mice [32]. This study found up-regulation of Keap1, down-regulation of Nrf2 nuclear translocation and its target antioxidant GST, HO-1 and NQO1, as well as high levels of ROS and TXNIP in fructose-fed rat livers and fructose-exposed BRL-3A and HepG2 cells. Moreover, we illuminated the relationship between Keap1 over-expression and Nrf2 antioxidant pathway inactivation induced by fructose. Nrf2 inhibition induced by fructose was mostly reversed by Keap1 siRNA, whereas Nrf2 activator tBHQ pre-treatment failed to alter Keap1 in BRL-3A cells, indicating that Keap1 over-expression may act upstream of Nrf2 inactivation. Additionally, Keap1 silence or Nrf2 activator tBHQ were normalized to LaminA, of Keap1, total Nrf2, GST, HO-1 and NQO1 were normalized to GAPDH or β-actin, respectively. All data are expressed as mean ± S.E.M.. P value was calculated by one-way ANOVA and further post hoc Dannelt testing. # P < 0.05, ## P < 0.01, ### P < 0.001 compared with controlvehicle; * P < 0.05, ** P < 0.01, *** P < 0.001 compared with fructose-vehicle; & P < 0.05 compared with fructose-Keap1 siRNA. UTR, untranslated region. pretreatment promoted Nrf2 nuclear translocation and induction of GST, HO-1 and NQO1 to quench fructose-induced ROS and reversed TXNIP over-expression in BRL-3A cells. There observations indicate that fructose-induced oxidative stress may be at least partly due to Keap1-mediated inactivation of Nrf2 in BRL-3A cells.
tBHQ is reported to inhibit NLRP3 inflammasome activation and consequent IL-1β production and secretion in cerebral ischemia reperfusion injury of rats [33]. Keap1 knockout with maximum Nrf2 activation ameliorates ethanol-induced liver lipid deposition by up-regulating SREBP-1 and SCD-1 in mice [11]. Nrf2 knockdown inhibits PPAR-α and CPT-1 but enhances SREBP-1c to increase lipid droplets as well as TG and TC levels in ethanol-simulated human hepatocytes cell lines, however, Nrf2 over-expression plasmid reverses these changes [34]. In this study, siRNA-mediated Keap1 knockdown down-regulated TXNIP to suppress NLRP3 inflammation activation, resulting in the regulation of PPAR-α, CPT-1, REBP-1 and SCD-1 with the reduction of TG and TC levels in fructose-exposed BRL-3A cells. Although Nrf2 antioxidant pathway activation mediated by tBHQ pre-treatment was unable to change fructose-induced Keap1 over-expression, this event could rapidly quench ROS to block TXNIP and NLRP3 inflammasome activation, and then restore lipid metabolism relative protein abnormal expression as well as TG and TC content reduction in BRL-3A cells. These results demonstrate that fructose-induced inhibition of Nrf2 antioxidant pathway via Keap1 may develop liver inflammation and lipid deposition.
Recently, more studies focus on the regulatory effects of miRNAs on redox homeostasis [31,35,36] MiR-200a is low-expression in hypoxiaexposed human adult cardiomyocyte line with oxidative stress [12]. However, little attention has been paid to miR-200a in fructose-induced liver oxidative stress, inflammation and lipid deposition. Interestingly, we found that Keap1 was a target gene of miR-200a in BRL-3A and HepG2 cells, and miR-200a low-expression was consistent with Keap1 up-regulation in fructose-fed rat livers and fructose-exposed BRL-3A and HepG2 cells. Moreover, miR-200a high-expression nearly Relative mRNA levels of Keap1 were normalized to β-actin. Western blot analysis of total Nrf2 and nuclear Nrf2 (C), GST, HO-1 and NQO1 protein levels (D) in rat livers. Relative protein levels of nuclear Nrf2 were normalized to LaminA, of Keap1, total Nrf2, GST, HO-1 and NQO1 were normalized to GAPDH or β-actin, respectively. All data are expressed as mean ± S.E.M. (n = 4 at least). P value was calculated by one-way ANOVA and further post hoc Dannelt testing. # P < 0.05, ## P < 0.01, ### P < 0.001 compared with control-vehicle; * P < 0.05, ** P < 0.01, *** P < 0.001 compared with fructose-vehicle. abrogated fructose-induced keap1 up-regulation and Nrf2 antioxidant pathway inactivation, and then ROS over-production and TXNIP overexpression in BRL-3A cells. Of note, aberrant miR-200a expression triggers TNF-α expression and inhibits PPAR-α, as well as increases SREBP-1c and SCD1 in fructose-exposed HepG2 cells [13]. Indeed, this study found that miR-200a mimic transfection reversed fructose-induced TXNIP-driven NLRP3 inflammasome activation, IL-1β production, and deregulation of PPAR-α, CPT-1, SREBP-1 and SCD-1 as well as TG and TC deposition in BRL-3A cells. Collectively, these results support the evidence that Keap1/Nrf2 pathway mediated by miR-200a low-expression is a key regulator of oxidative stress in fructose-induced liver inflammation and lipid deposition. This could be of potential therapeutic relevance.
In earlier reports, polydatin suppresses NLRP3 inflammasome activation and ameliorates potassium oxonate-induced kidney inflammation in rats [20], and enhances PPAR-α and inhibits SCD-1 in animal models induced by streptozocin or a high-fat diet [21,22]. In this study, we observed that polydatin and pioglitazone restored fructose-induced TXNIP over-expression, NLRP3 inflammasome activation, IL-1β production and secretion, and deregulation of PPAR-α, CPT-1, SREBP-1 and SCD-1 with TG and TC deposition in rat livers and BRL-3A and HepG2 cells. Enhancement of Nrf2 nuclear translocation through Keap1 silence up-regulates HO-1 and inhibits palmitate-induced ROS overproduction in HepG2 cells [6]. We also found that polydatin and pioglitazone decreased Keap1 mRNA and protein levels, increased Nrf2 nuclear translocation with induction of GST, HO-1 and NQO1 to reduce ROS production in fructose-fed rats and fructose-exposed BRL-3A and HepG2 cells. Further results from Keap1 siRNA and tBHQ pretreatment supported that polydatin and pioglitazone effectively down-regulated Keap1 to activate Nrf2 antioxidant pathway, resulting in the suppression of ROS-driven TXNIP and NLRP3 inflammasome activation as well as normalization of lipid metabolism-related proteins in BRL-3A cells.
MiR-200a high-expression can inhibit Keap1 and activate Nrf2 antioxidant pathway, and then quench ROS [12]. In this study, we firstly found that polydatin and pioglitazone up-regulated miR-200a expression in rat livers and BRL-3A and HepG2 cells under high fructose stimulation. Moreover, they up-regulated miR-200a to down-regulate Keap1 and activate Nrf2 antioxidant pathway to repress ROS-driven TXNIP and NLRP3 inflammasome activation as well as lipid metabolism-related protein dysregulation. Therefore, the regulation of polydatin and pioglitazone on miR-200a-targeted Keap1/Nrf2 pathway is required for the attenuation of fructose-induced inflammation and lipid deposition in BRL-3A cells. Taken together, these data further support the evidence that polydatin and pioglitazone reduce oxidative stress by increasing miR-200a to regulate Keap1/Nrf2 pathway in the protection against fructose-induced liver inflammation and lipid deposition.
In conclusion, our data for the first time demonstrated that fructoseinduced miR-200a low-expression increased Keap1 to inhibit Nrf2 antioxidant pathway, and then caused ROS-driven TXNIP to promote NLRP3 inflammasome activation and lipid metabolism-related protein dysregulation, resulting in liver inflammation and lipid deposition. Polydatin increased miR-200a expression to decrease Keap1 and activate Nrf2 antioxidant pathway, and then blocked ROS-driven TXNIP to suppress NLRP3 inflammasome activation and regulated lipid metabolism-related proteins, protecting against fructose-induced inflammation and lipid deposition. This study supports the notion that the enhancement of miR-200a to control Keap1/Nrf2 pathway by hepatoprotection agent polydatin is a therapeutic strategy for the prevention and treatment of fructose-associated liver inflammation and lipid deposition. Fig. 8. The hypothetical mechanisms by which polydatin prevents fructoseinduced in liver inflammation and lipid deposition through increasing miR-200a to regulate Keap1/Nrf2 pathway. Fructose-induced miR-200a low-expression increased Keap1 to inhibit Nrf2 antioxidant pathway, and then caused ROS-driven TXNIP to promote NLRP3 inflammasome activation and lipid metabolism-related protein dysregulation, resulting in liver inflammation and lipid deposition. Polydatin protected fructose-induced liver inflammation and lipid deposition by which increased miR-200a expression to decrease Keap1 and activate Nrf2 antioxidant pathway, and then blocked ROS-driven TXNIP to suppress NLRP3 inflammasome activation and regulated lipid metabolism-related proteins.